戻る
CRISPR Therapeutics Maintains "Outperform" Rating Amidst Phase 2 Thromboembolism Trial Initiation
戻る
株式ニュース
テーマ
CRISPR Therapeutics Maintains "Outperform" Rating Amidst Phase 2 Thromboembolism Trial Initiation
AIヘルスケア
CRISPR Therapeutics Maintains "Outperform" Rating Amidst Phase 2 Thromboembolism Trial Initiation
Edgen Stock
·
Oct 02 2025, 14:23
共有先
共有先
リンクをコピー
ソース：
[1] BMO Reaffirms Outperform on CRISPR Therapeutics (CRSP) After Sirius Collaboration
[2] BMO Capital reiterates Outperform on CRISPR Therapeutics stock, sees potential in thrombosis market - Investing.com
[3] CRISPR Therapeutics Advances Gene-Editing Pipeline Amidst Accelerating Casgevy Sales
Edgen Stock·Oct 02 2025, 14:23Edgen Stock·Oct 02 2025, 14:23
Edgen Stock·Oct 02 2025, 14:23